An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral naive Subjects: Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir.

Trial Profile

An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral naive Subjects: Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2016

At a glance

  • Drugs Darunavir (Primary) ; Darunavir/ritonavir (Primary) ; Raltegravir (Primary) ; Ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms NEAT001
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Oct 2016 Results (n=343) of the cognitive sub-study evaluating changes in cognitive function in HIV-positive antiretroviral naive subjects were published in the JAIDS
    • 25 Feb 2016 Results of sub-study (n=146) presented at the 23rd Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top